Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Glass

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Seminars in Hematology|January 29, 2014
Allogeneic transplantation in T-cell lymphomasNorbert Schmitz, Huei-Shan Wu, Bertram Glass
Haematologica|November 21, 2007
Allogeneic transplantation in lymphoma: current statusNorbert Schmitz, Peter Dreger, Bertram Glass, et al.
Revista Iberoamericana De Micologia|July 21, 2006
A case of pulmonary aspergillosis with lack of response to caspofunginReinhard Rüchel, Christine Perske, Bertram Glass, et al.
Annals of Hematology|September 4, 2009
Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphomaAndrea Borgerding, Justin Hasenkamp, Bertram Glass, et al.
Annals of Hematology|October 14, 2009
Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cellsJustin Hasenkamp, Andrea Borgerding, Gerald Wulf, et al.
Experimental Hematology|June 9, 2004
Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectorsRoland Schroers, York Hildebrandt, Justin Hasenkamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab eraMarita Ziepert, Dirk Hasenclever, Evelyn Kuhnt, et al.
Experimental Hematology|January 9, 2010
B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expressionAndrea Borgerding, Justin Hasenkamp, Michael Engelke, et al.
Oncology Research and Treatment|December 17, 2020
Decreased Incidence of Oncology Admissions in 75 Helios Hospitals in Germany during the COVID-19 PandemicPeter Reichardt, Andreas Bollmann, Sven Hohenstein, et al.
Transplantation and Cellular Therapy|January 28, 2024
Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-AnalysisNico Gagelmann, Michael Bishop, Francis Ayuk, et al.
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Seminars in Hematology|January 29, 2014
Allogeneic transplantation in T-cell lymphomasNorbert Schmitz, Huei-Shan Wu, Bertram Glass
Haematologica|November 21, 2007
Allogeneic transplantation in lymphoma: current statusNorbert Schmitz, Peter Dreger, Bertram Glass, et al.
Revista Iberoamericana De Micologia|July 21, 2006
A case of pulmonary aspergillosis with lack of response to caspofunginReinhard Rüchel, Christine Perske, Bertram Glass, et al.
Annals of Hematology|September 4, 2009
Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphomaAndrea Borgerding, Justin Hasenkamp, Bertram Glass, et al.
Annals of Hematology|October 14, 2009
Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cellsJustin Hasenkamp, Andrea Borgerding, Gerald Wulf, et al.
Experimental Hematology|June 9, 2004
Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectorsRoland Schroers, York Hildebrandt, Justin Hasenkamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab eraMarita Ziepert, Dirk Hasenclever, Evelyn Kuhnt, et al.
Experimental Hematology|January 9, 2010
B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expressionAndrea Borgerding, Justin Hasenkamp, Michael Engelke, et al.
Oncology Research and Treatment|December 17, 2020
Decreased Incidence of Oncology Admissions in 75 Helios Hospitals in Germany during the COVID-19 PandemicPeter Reichardt, Andreas Bollmann, Sven Hohenstein, et al.
Transplantation and Cellular Therapy|January 28, 2024
Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-AnalysisNico Gagelmann, Michael Bishop, Francis Ayuk, et al.
Pageof 10